Health Boards
This study looked at the efficacy response rates and safety outcomes through 120 weeks for patients with moderate to severe psoriasis who are treated with Siliq / Kyntheum (brodalumab)
Source: onlinelibrary.wiley.com
*Early view funding unknown
Kyntheum / Siliq (brodalumab)
Quote:
Background
Brodalumab is a monoclonal antibody that blocks multiple interleukin-17 family cytokines by binding to the shared A subunit of the interleukin-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated.
Objectives
To assess efficacy response rates and safety outcomes through 120 weeks for patients with moderate-to-severe psoriasis who received brodalumab.
Methods
Safety and efficacy data were pooled for patients from AMAGINE-2 and -3 who received continuous brodalumab 210 mg every 2 weeks, or brodalumab 210 mg every 2 weeks after receiving either brodalumab 140 mg or placebo through Week 12. Efficacy data are presented using observed data, non-responder imputation (NRI), and a combination of NRI and missing at random assumption to account for missing data. Absolute PASI scores are presented using mixed-effect model repeated measure modelling and multiple imputation.
Results
Based on observed data at Week 120, 86% of the continuous brodalumab 210 mg group achieved PASI 90 and 74% achieved PASI 100. At Week 12, 58% of this group achieved absolute PASI ≤1; this proportion increased to approximately 80% at Week 52 and persisted through Week 120.
Among patients receiving continuous brodalumab 210 mg, median duration of brodalumab exposure was 747 days, and the overall exposure-adjusted event rate of treatment emergent adverse events per 100 patient-years was 329. Safety through 120 weeks was comparable to the results of the primary AMAGINE-2 and -3 studies. Patients who switched to brodalumab 210 mg after receiving either brodalumab 140 mg or placebo through Week 12 showed similar skin clearance and safety profiles.
Conclusions
Brodalumab treatment was well tolerated and resulted in high levels of skin clearance that were rapidly achieved and maintained through Week 120, supporting its long-term efficacy and safety profile.
Source: onlinelibrary.wiley.com
*Early view funding unknown
Kyntheum / Siliq (brodalumab)
